Viral hepatitis continues to be a major health concern leading to hepatic decompensation ranging from acute hepatitis to cirrhosis and hepatocellular carcinoma.The hepatic and extrahepatic manifestations are not only ...Viral hepatitis continues to be a major health concern leading to hepatic decompensation ranging from acute hepatitis to cirrhosis and hepatocellular carcinoma.The hepatic and extrahepatic manifestations are not only debilitating but also associated with a significant economic burden.Over the last two decades,the field of virology has made significant breakthroughs leading to a better understanding of the pathophysiology of viral hepatitis,which in turn has led to new therapeutic options.The advent of direct-acting antiviral agents changed the landscape of hepatitis C virus(HCV)therapy,and new drugs are in the pipeline for chronic hepatitis B virus(HBV)treatment.There has also been a significant emphasis on screening and surveillance programs,widespread availability of vaccines,and linkage of care.Despite these efforts,significant gaps persist in care,and there is a pressing need for increased collaboration and teamwork across the globe to achieve a reduction of disease burden and elimination of HBV and HCV.展开更多
Hepatocellular carcinoma(HCC)is a leading cause of liverrelated death worldwide.Hepatitis C virus(HCV)infection is a major cause of advanced hepatic fibrosis and cirrhosis,with significantly increased risk for develop...Hepatocellular carcinoma(HCC)is a leading cause of liverrelated death worldwide.Hepatitis C virus(HCV)infection is a major cause of advanced hepatic fibrosis and cirrhosis,with significantly increased risk for development of HCC.The morbidity and mortality of HCV-related HCC remains high,as rates of HCV cirrhosis continue to increase.The long-term goal of antiviral therapy for chronic HCV is to reduce complications from cirrhosis,including HCC.The advent of new direct-acting antivirals with high rates of virological clearance has revolutionized cure of HCV infection.While the development of HCC in HCV patients who achieve disease sustained virologic response is reduced,these patients remain at risk for HCC,particularly those patients with advanced fibrosis and cirrhosis.This review outlines the epidemiology of HCC in chronic HCV,various mechanisms,risk factors and pathophysiology that contribute to this disease process,screening recommendations,and the available data on the impact of new direct-acting antiviral treatment on the development on HCC.展开更多
文摘Viral hepatitis continues to be a major health concern leading to hepatic decompensation ranging from acute hepatitis to cirrhosis and hepatocellular carcinoma.The hepatic and extrahepatic manifestations are not only debilitating but also associated with a significant economic burden.Over the last two decades,the field of virology has made significant breakthroughs leading to a better understanding of the pathophysiology of viral hepatitis,which in turn has led to new therapeutic options.The advent of direct-acting antiviral agents changed the landscape of hepatitis C virus(HCV)therapy,and new drugs are in the pipeline for chronic hepatitis B virus(HBV)treatment.There has also been a significant emphasis on screening and surveillance programs,widespread availability of vaccines,and linkage of care.Despite these efforts,significant gaps persist in care,and there is a pressing need for increased collaboration and teamwork across the globe to achieve a reduction of disease burden and elimination of HBV and HCV.
基金The work was supported by a faculty development grant to AKS by the American College of Gastroenterology
文摘Hepatocellular carcinoma(HCC)is a leading cause of liverrelated death worldwide.Hepatitis C virus(HCV)infection is a major cause of advanced hepatic fibrosis and cirrhosis,with significantly increased risk for development of HCC.The morbidity and mortality of HCV-related HCC remains high,as rates of HCV cirrhosis continue to increase.The long-term goal of antiviral therapy for chronic HCV is to reduce complications from cirrhosis,including HCC.The advent of new direct-acting antivirals with high rates of virological clearance has revolutionized cure of HCV infection.While the development of HCC in HCV patients who achieve disease sustained virologic response is reduced,these patients remain at risk for HCC,particularly those patients with advanced fibrosis and cirrhosis.This review outlines the epidemiology of HCC in chronic HCV,various mechanisms,risk factors and pathophysiology that contribute to this disease process,screening recommendations,and the available data on the impact of new direct-acting antiviral treatment on the development on HCC.
